Pictured: Dr. Daniel Rayson, Oncologist and QEII Division Head, Medical Oncology & Dr. Steven Burrell, Radiologist and QEII Head, Nuclear Medicine
Neuroendocrine cancers are on the rise, and we are proud to be among those at the forefront of doing better for these patients.
Lack of access to the innovative gallium-68 DOTATATE tracer is not a QEII issue, but a national one, and we’re excited to be among the first centres in Canada to offer this to patients locally.
When it’s your loved one in the scanner, you will do anything in your power to help them get better. With your gift, you are doing just that – bringing the best options to a patient population that has traditionally gone years of their lives without answers.
Our goal is to have gallium-68 DOTATATE available at the QEII this spring. The sooner we have it in place, the sooner our patients can benefit from it. Please donate by March 31st to help us raise $200,000 to meet this urgent need.
A multidisciplinary group across many specialties, our QEII neuroendocrine tumour disease team delivers the most advanced, integrated care to the patients we serve.
When we are supported by folks like you, amazing things happen. This is just the beginning of more discoveries in cancer imaging, as research unfolds and we learn more ways to treat cancer. On behalf of the lives you will help save, thank you, sincerely, for helping us realize this dream.
- Dr. Daniel Rayson, Oncologist and QEII Division Head, Medical Oncology & Dr. Steven Burrell, Radiologist and QEII Head, Nuclear Medicine
To learn more and help bring better cancer imaging technology home to the QEII, click here.